浸润性浆细胞样尿路上皮癌:E-钙黏蛋白与P120连环蛋白的比较研究
该研究对33例浸润性浆细胞样尿路上皮癌(PUC)进行E-钙黏蛋白和P120全切片免疫组化分析,并检测部分病例CDH1突变。结果显示E-钙黏蛋白和P120异常染色率均为73%,两者一致率达94%,CDH1突变见于50%受检病例。P120联合E-钙黏蛋白染色有助于PUC的诊断。
要点
- PUC中E-钙黏蛋白和P120异常染色率均为73%。
- E-钙黏蛋白与P120免疫表型一致率达94%。
- CDH1突变见于50%受检PUC病例。
核心结论
- PUC中E-钙黏蛋白和P120异常染色率均为73%,两者高度一致(94%)。
- 联合P120染色可作为PUC的辅助诊断工具,尤其在某些形态不典型或E-钙黏蛋白胞质染色干扰时。
研究设计与样本
- 回顾性收集PUC活检、经尿道切除和膀胱切除标本,进行E-钙黏蛋白和P120全切片免疫组化分析。
- 33例PUC按形态分为经典型、多形性或促结缔组织增生型,部分病例检测CDH1突变。
主要发现
- E-钙黏蛋白异常染色24/33(73%),其中完全缺失17/24(71%),胞质染色7/24(29%)。
- P120异常染色24/33(73%),表现为膜染色缺失伴胞质反应性。
- 仅2例E-钙黏蛋白/P120免疫表型不一致(一致率94%)。
- 3种形态学分类间染色无显著差异。
- CDH1突变见于4/8(50%)病例,其中3/4(75%)分子与免疫表型匹配。
关键数值与推荐
- E-钙黏蛋白异常染色率73%,与已发表病例的meta分析(74%)相似。
- P120异常染色率73%,与E-钙黏蛋白一致率94%。
- CDH1突变率50%(4/8),突变病例中75%免疫表型匹配。
临床怎么用
- PUC的诊断仍基于组织学,但联合P120染色可提高诊断准确性。
- 对于形态不典型(如促结缔组织增生型)或E-钙黏蛋白胞质染色干扰的病例,建议加做P120染色。
局限性
- CDH1突变检测仅限部分病例(8例),样本量有限。
- 未发现染色与形态学分类的显著差异,可能受样本量限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive plasmacytoid urothelial carcinomas (PUCs) are an uncommon aggressive variant, which often shows immunohistochemical loss of E-cadherin, underlying its distinct discohesive histology. The marker P120 (well described in breast pathology as being a diagnostic tool alongside E-cadherin for lobular neoplasia) has not been evaluated in PUCs. Biopsies, transurethral resections, and cystectomies of PUCs were collected, and whole-slide immunohistochemical analysis of E-cadherin and P120 was applied. A subset of cases were also tested for CDH1 mutation. PUC cases were stratified into morphologic categories of classic, pleomorphic, or desmoplastic. For E-cadherin, 24 of 33 (73%) cases showed an abnormal staining pattern, consisting of complete absence of staining (17/24; 71%) or cytoplasmic staining (7/24; 29%). For P120, 24 of 33 (73%) cases showed an abnormal staining pattern, consisting of loss of membranous staining with cytoplasmic reactivity. Only 2 cases showed a discordant E-cadherin/P120 immunoprofile (94% concordance). Significant staining differences among the 3 morphologic categories were not found. CDH1 mutation was found in 4 of 8 (50%) of cases, with 3 of 4 (75%) cases showing matched molecular/immunoprofile reactivity. No cases with CDH1 mutation showed discordant pattern E-cadherin/P120 immunoreactivity. Our rate of aberrant E-cadherin immunoreactivity in PUCs (73%) is similar to a meta-analysis of published cases (74%). We also report an identical rate of aberrant P120 immunoreactivity in PUCs (73%). While PUC remains a histologic diagnosis, in a subset of cases showing a less appreciated pattern (such as desmoplastic) or confounding cytoplasmic E-cadherin reactivity, the utility of paired P120 staining may be a useful diagnostic tool.
引用
- Sangoi AR, Chan E, Stohr BA, et al. Invasive plasmacytoid urothelial carcinoma: A comparative study of E-cadherin and P120 catenin. Hum Pathol. 2020. PMID: 32673685. doi:10.1016/j.humpath.2020.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。